Company Research Report: Raydiant Oximetry, Inc.

Company Overview

• Name: Raydiant Oximetry, Inc.

• Mission: Raydiant Oximetry aims to profoundly reduce the rising mortality and morbidity rates among mothers and babies during childbirth by developing innovative, non-invasive monitoring technology.

• Founded: 2016

• Founder: Neil P. Ray, MD

• Key People:

• Neil Ray, MD - Founder and CEO

• Russ DeLonzor, MBA - COO

• Debra Snowdale - CFO

• Mark Rosen, MD - Chief Medical Officer

• Paul Stetson, PhD - Chief Scientific Officer

• Eric Johansson - VP, R&D

• Laura Kemp - VP, Clinical/Regulatory Affairs

• Dante Salvetti - VP, Commercial Development

• Denise Malvehy - VP, Global Marketing

• Headquarters: San Ramon, California, USA

• Number of Employees: 11-50 employees

• Revenue: No information is available.

• Known For: Raydiant Oximetry is known for developing Lumerah™, a non-invasive sensor technology intended to measure fetal oxygenation levels during childbirth, aiming to improve outcomes and reduce unnecessary cesarean sections.

Products

Lumerah™

• Description: Lumerah™ is a non-invasive fetal pulse oximeter designed to directly measure fetal blood oxygen saturation during labor.

• Key Features:

• Accurate: Improves sensitivity and specificity in detecting fetal distress compared to traditional fetal heart rate monitors.

• Affordability: Offered at a price point designed to make it accessible and create a new standard of care.

• FDA Breakthrough Status: Received fast-track market approval status.

• Portability: Single-use and easy to deploy within clinical settings.

• Risk Stratification: Provides healthcare professionals with greater insight and confidence during labor.

Recent Developments

• New Products/Features:

• In addition to Lumerah™, the company also developed Daisy™, a vacuum-induced surgical tool for OB/GYN applications.

• Recent Partnerships and Funding:

• September 24, 2024: Received a $1 million grant from the Bill & Melinda Gates Foundation to advance fetal monitoring technology.

• November 02, 2021: Raised $5 million in Series A2 financing led by Avestria Ventures.

• Received grants for signal processing work in collaboration with the Tyndall National Institute in Ireland, supported by the Disruptive Technologies Innovation Fund from Ireland’s Department of Enterprise, Trade and Employment.

• Achievements:

• Lumerah™ awarded FDA Breakthrough Device Status in 2018, further validated by winning the NIH RADx® Tech Fetal Monitoring Challenge in 2024, securing $750,000 in prize money.

• Clinical Studies:

• Lumerah™ enrolled its first participant in an Early Feasibility Study on May 15, 2024, under an Investigational Device Exemption.

• Office Relocation: Moved offices to San Ramon, California after graduating from the Fogarty Institute.

In conclusion, Raydiant Oximetry, Inc. is making significant strides in maternal-fetal medicine by focusing on innovative, non-invasive devices aimed to improve outcomes during childbirth. The company's dedication to reducing unnecessary cesarean sections while maintaining high industry standards is evident in its recent developments and strategic partnerships.